Latest Articles
-
After A 40% Rally Should You Pick Boston Scientific Over Abbott?
Medical Devices companies – Abbott (NYSE:ABT) and Boston Scientific (NSYE:BSX) – have seen their stock price grow over 40% since the March 23 lows. This can partly be attributed to the overall recovery seen in the market over the recent weeks, ...
-
Best Medical Devices Stock: DexCom Or Abbott?
Based on year-to-date returns, DexCom stands out with 43% gains vis-a-vis -9% decline for broader S&P 500. DexCom’s glucose monitoring devices, which can be used at-home, are seeing a surge in demand, amid movement restrictions and lock...
-
Best Coronavirus Testing Stocks: Abbott, Quest Or Chembio Diagnostics?
Testing is viewed as key to containing the spread of the Coronavirus pandemic and re-opening the economy until a safe vaccine is developed. For instance, the U.S. government on Monday indicated that it would scale up its testing strategy signific...
-
What’s The Upside For Abbott From $85?
Abbott’s (NYSE: ABT) stock declined a mere 1.3% from $86 in the beginning of this year to $85 on April 13, compared to a 15% decline for the broader S&P 500. While Abbott’s stock has outperformed thus far, we believe there is only...
-
Ride Abbott To $100 With Its New COVID-19 Test?
Based on historical performance, Abbott Labs (NYSE: ABT) appears to be a better bet compared to Medtronic (NYSE:MDT) in the current crisis. The current coronavirus crisis will likely impact medical devices company on two fronts, 1. supply chain d...
-
Will Abbott Stock Outperform The Broader Market Post Coronavirus?
Abbott’s (NYSE: ABT) stock could outperform the broader S&P 500 index post coronavirus and oil price war crisis, going by trends seen during the 2008 slowdown, where it fell 11% from the approximate pre-crisis peak in 2008, and recover...
-
Can Abbott’s Revenue Continue To Grow In Double-Digits?
We don’t expect Abbott’s (NYSE:ABT) revenue to grow in double-digits in the near term. The company has seen its revenue grow at a CAGR of 12.4% from $20.4 billion in 2015 to $31.9 billion in 2019, but this growth was largely driven b...
-
What To Expect From Abbott’s Full-Year 2019 Earnings
Abbott (NYSE:ABT) will release its Q4 and full-year 2019 results on Wednesday, January 22. For full-year 2019, Trefis estimates that the company will report: Revenues of $31.8 billion, reflecting 4.1% y-o-y growth, primarily driven by the comp...
-
How Much Does Abbott Spend On SG&A?
Abbott (NYSE:ABT) spent $6.5 billion on selling, general & administrative (SG&A) expense in 2014, and the figure increased to $9.7 billion in 2018, driven by acquisitions, growth in sales, and the launch of new products. As a percentage ...
-
How Does Abbott’s Revenue And Other Key Metrics Compare With That of Boston Scientific?
Abbott (NYSE:ABT) and Boston Scientific (NYSE:BSX) are both engaged in the medical devices business. Abbott generates 3x the revenue when compared to Boston Scientific. For both the companies, revenue over the past few years has been impacted by...
-
How Much Revenue Does Abbott Generate From The United States?
Abbott (NYSE:ABT) generates its revenue from sales of medical devices across the globe. The company generated $11 billion in sales in the United States, accounting for over one-third of its total revenue in 2018. This figure has been on a rise a...
-
How Much Can Abbott’s Revenue Grow In The Coming Years?
Abbott Labs (NYSE:ABT) is a diversified healthcare conglomerate with a global presence. The firm operates in four main segments: Medical Devices, Diagnostics, Nutritional, and Established Pharmaceuticals. Medical Devices has become the company&#...
-
What’s Fueling Abbott’s Stock Price Growth?
Abbott Labs’ (NYSE:ABT) share price has more than doubled over the last three years. This can be attributed to steady growth in its revenues, margin expansion, price to earnings multiple growth, and lower share count. Note that Abbott acqu...
-
How Does Abbott’s Established Pharmaceuticals Business Compare With Its Peers?
Abbott Labs’ (NYSE:ABT) established pharmaceuticals business offers a broad line of branded pharmaceuticals, manufactured worldwide, and marketed and sold outside the U.S. The major products sold through this segment include Creon, Brufen,...
-
What’s Driving Our $81 Price Estimate For Abbott Laboratories?
Abbott Labs’ (NYSE:ABT) stock price has gained over 8% year-to-date. This is much higher than the overall healthcare sector returns of close to 4%. The stock price seems to have some more room for growth, in our view. This note details Tre...
